Teva Pharmaceutical’s DuoResp Spiromax multidose DPI has won a Silver award at the 2015 Medical Design Excellence Awards (MDEA), with Gerresheimer receiving credit as a supplier. DuoResp Spiromax received European marketing authorization in April 2014.
Teva Global Specialty Medicines President and CEO Rob Koremans commented, “Innovative, patient-focused design is extremely important at a time when real-world behaviors and outcomes are what count. We are incredibly proud to be leading the way in providing people with asthma and COPD with inhalers that recognize and support their needs and long term health, and are delighted with this prestigious acknowledgment for DuoResp Spiromax.”
Read the Teva press release.
